Myriad, Gene and UnitedHealthcare

Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...
Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...
BRANDON, FL, UNITED STATES, November 3, 2024 /EINPresswire / -- Learning to Achieve Wellness has carved out a unique space in the world of mental < ...
Wells Fargo analyst Steve Baxter maintained a Buy rating on UnitedHealth (UNH – Research Report) yesterday and set a price target of ...
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...
With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.